ArticleJournal of leukocyte biology2012
FcγRI mediates serum amyloid P inhibition of fibrocyte differentiation.
Article in Journal of leukocyte biology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 52 citations in OpenAlex.
- Circulating Fibrocytes: Cellular Mediators of Tissue Fibrosis.International journal of molecular sciences · 2026Review
- Inhibitors of the Sialidase NEU3 as Potential Therapeutics for Fibrosis.International journal of molecular sciences · 2022Review
- The sialidase NEU3 promotes pulmonary fibrosis in mice.Respiratory research · 2022Article
- Serum Proteomic Analysis Identifies SAA1, FGA, SAP, and CETP as New Biomarkers for Eosinophilic Granulomatosis With Polyangiitis.Frontiers in immunology · 2022Article
- Serum Amyloid P inhibits single stranded RNA-induced lung inflammation, lung damage, and cytokine storm in mice.PloS one · 2021Article
- Article
- Serum Amyloid P and a Dendritic Cell-Specific Intercellular Adhesion Molecule-3-Grabbing Nonintegrin Ligand Inhibit High-Fat Diet-Induced Adipose Tissue and Liver Inflammation and Steatosis in Mice.The American journal of pathology · 2019Article
- Monocyte-to-macrophage switch reversibly impaired by Ibrutinib.Oncotarget · 2019Article
- The emerging role of fibrocytes in ocular disorders.Stem cell research & therapy · 2018Review
- The Development of Serum Amyloid P as a Possible Therapeutic.Frontiers in immunology · 2018Review
- Exploring the Immunomodulatory Moonlighting Activities of Acute Phase Proteins for Tolerogenic Dendritic Cell Generation.Frontiers in immunology · 2018Review
- Myeloproliferative leukemia protein activation directly induces fibrocyte differentiation to cause myelofibrosis.Leukemia · 2017Article
- Sialidase inhibitors attenuate pulmonary fibrosis in a mouse model.Scientific reports · 2017Article
- Functional similarities between the dictyostelium protein AprA and the human protein dipeptidyl-peptidase IV.Protein science : a publication of the Protein Society · 2017Article
- Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies.Haematologica · 2016Review
- TNF-α-stimulated fibroblasts secrete lumican to promote fibrocyte differentiation.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
- New therapies for hepatic fibrosis.Clinics and research in hepatology and gastroenterology · 2015Review
- Novel association between serum pentraxin-2 levels and advanced fibrosis in well-characterised patients with non-alcoholic fatty liver disease.Alimentary pharmacology & therapeutics · 2015Article
- A brief exposure to tryptase or thrombin potentiates fibrocyte differentiation in the presence of serum or serum amyloid p.Journal of immunology (Baltimore, Md. : 1950) · 2015Article
- The long pentraxin PTX3 promotes fibrocyte differentiation.PloS one · 2015Article
Corrections and comments
- Commented on by
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Fibrotic diseases, such as cardiac and pulmonary fibrosis, have a poor prognosis with no FDA approved therapies. Monocyte-derived, fibroblast-like cells, called fibrocytes, participate in the formation of fibrotic lesions. The conserved pentraxin protein SAP inhibits fibrocyte differentiation in cell culture, and injections of SAP significantly reduce fibrosis in several animal models. SAP binds to the receptors for the Fc portion of IgG (FcγR) and has been crystallized bound to FcγRIIa (CD32a). The in vivo activity of SAP appears to be dependent on the FcRγ. We find that mutagenesis of the residues critical for SAP binding to FcγRIIa only moderately decreases the ability of SAP to inhibit fibrocyte differentiation. In murine cells, deletion of FcRγ or FcγRI (CD64) significantly reduced sensitivity to SAP. Deletion of the combination of FcγRIIb, FcγRIIIa, and FcγRIV did not significantly affect sensitivity to SAP, whereas deletion of just the inhibitory receptor FcγRIIb (CD32b) increased sensitivity to SAP. In human cells, siRNA-mediated reduction of FcRγ or FcγRI levels significantly decreased sensitivity to SAP, whereas reduction of FcγRIIb levels increased sensitivity to SAP. These observations suggest that SAP, at least in part, uses FcγRI and FcRγ to inhibit fibrocyte differentiation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.